JP2018502550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502550A5 JP2018502550A5 JP2016569603A JP2016569603A JP2018502550A5 JP 2018502550 A5 JP2018502550 A5 JP 2018502550A5 JP 2016569603 A JP2016569603 A JP 2016569603A JP 2016569603 A JP2016569603 A JP 2016569603A JP 2018502550 A5 JP2018502550 A5 JP 2018502550A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- conservative substitutions
- acid modifications
- acid modification
- modifications
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 336
- 238000012986 modification Methods 0.000 claims 333
- 230000004048 modification Effects 0.000 claims 333
- 238000006467 substitution reaction Methods 0.000 claims 184
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 239000000833 heterodimer Substances 0.000 claims 33
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 4
- 238000004113 cell culture Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims 3
- 238000001890 transfection Methods 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 241000699800 Cricetinae Species 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000003146 transient transfection Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154055P | 2015-04-28 | 2015-04-28 | |
| US62/154,055 | 2015-04-28 | ||
| PCT/IB2015/054107 WO2015181805A1 (en) | 2014-05-28 | 2015-05-29 | Modified antigen binding polypeptide constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020137041A Division JP7183221B2 (ja) | 2015-04-28 | 2020-08-14 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018502550A JP2018502550A (ja) | 2018-02-01 |
| JP2018502550A5 true JP2018502550A5 (enExample) | 2018-07-05 |
| JP7103751B2 JP7103751B2 (ja) | 2022-07-20 |
| JP7103751B6 JP7103751B6 (ja) | 2022-08-15 |
Family
ID=58848603
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569603A Active JP7103751B6 (ja) | 2015-04-28 | 2015-05-29 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
| JP2020137041A Active JP7183221B2 (ja) | 2015-04-28 | 2020-08-14 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
| JP2022186638A Pending JP2023027107A (ja) | 2015-04-28 | 2022-11-22 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
| JP2024104675A Pending JP2024125389A (ja) | 2015-04-28 | 2024-06-28 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020137041A Active JP7183221B2 (ja) | 2015-04-28 | 2020-08-14 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
| JP2022186638A Pending JP2023027107A (ja) | 2015-04-28 | 2022-11-22 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
| JP2024104675A Pending JP2024125389A (ja) | 2015-04-28 | 2024-06-28 | 修飾された抗原結合ポリペプチド構築物及びその使用 |
Country Status (3)
| Country | Link |
|---|---|
| JP (4) | JP7103751B6 (enExample) |
| KR (2) | KR20240093883A (enExample) |
| CN (1) | CN106661121A (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| MX2021002690A (es) * | 2018-09-07 | 2021-05-12 | Pfizer | Anticuerpos anti-avb8 y composiciones y usos de los mismos. |
| KR20210108421A (ko) * | 2018-12-24 | 2021-09-02 | 사노피 | 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질 |
| CN113795502B (zh) * | 2019-04-26 | 2024-06-11 | 轩竹生物科技股份有限公司 | Cd80变体蛋白及其应用 |
| CN117440969A (zh) * | 2021-01-11 | 2024-01-23 | 阿迪马布有限责任公司 | 被工程化为优先进行ch3异源二聚化的变体ch3结构域、包括所述变体ch3结构域的多特异性抗体和其制备方法 |
| AU2022261269A1 (en) * | 2021-04-23 | 2023-11-09 | Chimagen Biosciences, Ltd | Heterodimeric antibodies and antigen-binding fragment thereof |
| JP2024544607A (ja) * | 2021-11-25 | 2024-12-03 | エフ． ホフマン－ラ ロシュ アーゲー | 少量の抗体副産物の定量 |
| CN114106192B (zh) * | 2021-12-20 | 2024-06-14 | 广州爱思迈生物医药科技有限公司 | 双特异性抗体及其应用 |
| WO2025167974A1 (zh) * | 2024-02-07 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 多特异性抗体或抗原结合片段 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010080538A1 (en) | 2008-12-19 | 2010-07-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP2035456A1 (en) * | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SG10201805291TA (en) * | 2011-10-27 | 2018-08-30 | Genmab As | Production of heterodimeric proteins |
| CN104640561A (zh) * | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US10077298B2 (en) * | 2012-11-28 | 2018-09-18 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| RU2729467C2 (ru) * | 2014-05-28 | 2020-08-06 | Займворкс Инк. | Модифицированные антигенсвязывающие полипептидные конструкции и их применение |
-
2015
- 2015-05-29 KR KR1020247017112A patent/KR20240093883A/ko active Pending
- 2015-05-29 CN CN201580036617.1A patent/CN106661121A/zh active Pending
- 2015-05-29 KR KR1020237002909A patent/KR102669686B1/ko active Active
- 2015-05-29 JP JP2016569603A patent/JP7103751B6/ja active Active
-
2020
- 2020-08-14 JP JP2020137041A patent/JP7183221B2/ja active Active
-
2022
- 2022-11-22 JP JP2022186638A patent/JP2023027107A/ja active Pending
-
2024
- 2024-06-28 JP JP2024104675A patent/JP2024125389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502550A5 (enExample) | ||
| JP7444381B2 (ja) | Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途 | |
| US20230295291A1 (en) | Engineered heterodimeric proteins | |
| Moore et al. | A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats | |
| JP2022088598A (ja) | ヘテロ二量体免疫グロブリン | |
| RU2016145906A (ru) | Модифицированные антигенсвязывающие полипептидные конструкции и их применение | |
| US20160009824A1 (en) | Tetravalent bispecific antibodies | |
| RU2015125486A (ru) | Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение | |
| US20110189203A1 (en) | Immunoglobulin constructs | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| TW202212358A (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| US20240092899A1 (en) | Bispecific antibody | |
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| Kim et al. | Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening | |
| Zhao et al. | A new approach to produce IgG4-like bispecific antibodies | |
| US20220372168A1 (en) | Multispecific fgf21 receptor agonists and their uses | |
| WO2025092987A1 (zh) | 基于Fc区的异二聚体分子及其用途 | |
| WO2024120199A1 (en) | Bispecific/multi-specific antibodies and uses thereof | |
| WO2024221187A1 (en) | Heteromultimer polypeptides | |
| WO2024027120A1 (en) | Multi-specific polypeptide complexes | |
| Jin et al. | The design and engineering of IgG-like bispecific antibodies | |
| WO2024017371A9 (zh) | 促进多特异性抗体的重链和轻链同源配对的突变体 | |
| WO2025255480A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2024037627A1 (zh) | 一种双特异性抗体及其应用 | |
| RU2018116846A (ru) | Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения |